Abbott Exits Boehringer Ingelheim Distribution Deal Early
This article was originally published in The Pink Sheet Daily
Executive Summary
Termination of the agreement to distribute Mobic, Flomax and Micardis in the U.S. is expected to boost Abbott’s gross margins, the company reports.
You may also be interested in...
Abbott Manufacturing Cuts Will Make Up For Lower Mobic Profits
Consolidation and staff reductions in global manufacturing operations are designed to improve gross margins, which have been negatively impacted by sales of lower margin products, such as Mobic and Flomax, which Abbott distributes under a deal with Boehringer. Abbott is cutting 700 manufacturing positions.
Abbott Flomax Reps Will Shift To Smaller Products Once Co-Promotion Deal Ends
The company will move from actively co-promoting to merely distributing Flomax at the end of August under its 1999 agreement with Boehringer Ingelheim. Tarka and Omnicef could pick up reps from the Flomax sales force, Abbott says.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.